FenXun Partners (Beijing)

Zhi Bao

FenXun Partners (Beijing)
Lawyer (Partner)

Mr. Bao is a partner of FenXun Partners and he heads the anti-monopoly practice group of FenXun Partners. Mr. Bao’s practice focuses on foreign direct investment, mergers and acquisitions, private equity and anti-monopoly, all disciplines which he made his own during his over seven years with the Ministry of Commerce (MOFCOM) in Beijing and subsequently at a leading PRC law firm. At MOFCOM, he spearheaded examination of numerous foreign direct investments, cross-border mergers and acquisitions, and anti-monopoly filings for companies engaged in M&A transactions. He also was a principal draftsman of key regulations relating to restructuring of domestic and offshore companies, and cross-border M&A transactions (for both unlisted and listed Chinese target companies, as well as both inbound and outbound transactions) and funds. As a partner of FenXun Partners, Mr. Bao has pioneered (and obtained approvals for) unique, tested transformations of offshore ownership transaction structures into onshore ownership structures for important clients. Mr. Bao has advised many multinational companies on regulatory aspects, including but not limited to anti-trust filing and national security review of their cross-border M&A transactions, as well as counselling them on the regulatory risks of their business behaviour.



339 Bulletin

Stephen Crosswell, Zhi Bao The Chinese Competition Authority imposes a fine totalling USD 45.62 million on its national power connection supplier for resale price maintenance (Bull)


The China’s State Administration for Market Regulation ("SAMR")’s local branch in Zhejiang Province on 27 September 2021 announced a fine of USD 45.62 million on Bull Group for resale price maintenance ("RPM"). The SAMR has historically taken a tough stance on RPM and its recent imposition of (...)

Zhi Bao, Laura Liu, Wenting Ge, Stephen Crosswell, Thomas Jenkins The Chinese SAMR fines 3 national pharmaceutical companies for abuse of dominance in the sale of an injectable pharmaceutical ingredient (Kanghui / Puyunhui / Taiyangshen)


On 9 April 2020, China’s State Administration for Market Regulation (SAMR) fined three domestic pharmaceutical companies Shandong Kanghui Medicine Company Limited ("Kanghui"), Weifang Puyunhui Pharmaceutical Company Limited ("Puyunhui") and Weifang Taiyangshen Company Limited Pharmaceutical (...)

Stephen Crosswell, Thomas Jenkins, Zhi Bao, Laura Liu, Wenting Ge The Chinese State Administration for Market Regulation ramps up antitrust enforcement by introducing 3 consolidated antitrust enforcement guidelines


This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Since September 2018, the State Administration for Market Regulation ("SAMR"), the consolidated Chinese competition authority, has strengthened its enforcement of (...)

Envoyer un message